KRAS,AACR25,lcsm,NSCLC

Mashup Score: 9

Zoldonrasib Shows ‘Encouraging’ Activity in Patients With NSCLC Harboring KRAS G12D Mutation - 6 day(s) ago

Zoldonrasib showed “encouraging initial antitumor activity” in patients with non–small cell lung cancer (NSCLC) who are harboring the KRAS G12D mutation at AACR 2025.

Source: www.lungcancerstoday.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Lung_Cancers
  
  🫁 Zoldonrasib showed “encouraging initial antitumor activity” in patients with NSCLC who are harboring the #KRAS G12D mutation, according to a study presented at #AACR25 by @KCArbourMD of @MSKCancerCenter. ➡️ Learn more: https://t.co/5yBae9deQH #lcsm #NSCLC @AACR https://t.co/CD9vvvkPfy